Harvard Bioscience Inc
$ 6.13
3.72%
17 Apr - close price
- Market Cap 26,429,500 USD
- Current Price $ 6.13
- High / Low $ 6.25 / 5.86
- Stock P/E N/A
- Book Value 3.07
- EPS -13.25
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE -1.47 %
- 52 Week High 9.46
- 52 Week Low 2.81
About
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
Analyst Target Price
$6.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-06 | 2025-08-11 | 2025-05-05 | 2025-03-05 | 2024-11-07 | 2024-08-08 | 2024-05-07 | 2024-03-07 | 2023-11-07 | 2023-08-08 | 2023-04-25 |
| Reported EPS | -0.6383 | -0.03 | -0.01 | -0.01 | 0.06 | -0.02 | -0.0673 | 0.02 | 0.04 | 0.01 | 0.04 | 0.06 |
| Estimated EPS | 0.04 | 0.01 | -0.005 | -0.01 | 0.05 | 0.03 | 0.05 | 0.02 | 0.05 | 0.04 | 0.06 | 0.05 |
| Surprise | -0.6783 | -0.04 | -0.005 | 0 | 0.01 | -0.05 | -0.1173 | 0 | -0.01 | -0.03 | -0.02 | 0.01 |
| Surprise Percentage | -1695.75% | -400% | -100% | 0% | 20% | -166.6667% | -234.6% | 0% | -20% | -75% | -33.3333% | 20% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.0 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $1.2832258065 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HBIO
2026-04-02 11:39:22
Harvard Bioscience CFO Mark T. Frost recently purchased 5,000 shares of HBIO common stock for $25,000, bringing his direct ownership to 17,500 shares. This insider transaction occurred despite the stock being down 27% year-to-date and followed a 10-for-1 reverse stock split. The company is pursuing a strategic plan for 2026 focusing on revenue growth and margin expansion, supported by a strong free cash flow yield of 26% according to InvestingPro.
2026-04-01 14:39:36
Harvard Bioscience CFO Mark T. Frost recently purchased 5,000 shares of HBIO stock valued at $25,000, bringing his direct ownership to 17,500 shares. This insider transaction occurred while the stock was down 27% year-to-date. The company recently reported Q4 2025 revenues exceeding guidance and provided positive outlook for 2026, though a 1-for-10 reverse stock split and analyst target adjustments have also occurred.
2026-04-01 13:39:36
Harvard Bioscience's CFO, Mark T. Frost, purchased 5,000 shares of common stock at $5.00 each in an open-market transaction, bringing his total direct holdings to 17,500 shares. This total includes restricted stock units and beneficially owned shares, which were adjusted following a 10-for-1 reverse stock split on March 13, 2026. This insider buying signals confidence in the company's future.
2026-04-01 13:39:36
Harvard Bioscience CFO Mark T. Frost received a grant of 30,000 Restricted Stock Units (RSUs) which will vest in three equal installments starting March 20, 2027. This equity compensation, not a market trade, brings his total common stock equivalents to 47,500. The company also underwent a 10-for-1 reverse stock split on March 13, 2026, which adjusted previously reported RSU and share counts.
2026-03-28 14:40:16
Harvard Bioscience (HBIO) recently saw its price target increased by 200.00%, raising it to 6.12. This significant adjustment reflects a new valuation or outlook for the company's stock.
2026-03-27 20:10:32
This article focuses on the debt to assets ratio of Harvard Bioscience, Inc. (MUN:HBI0). It provides trading information from the Munich Stock Exchange and indicates that the market was closed at the time of the overview. The content primarily serves as a placeholder for financial data that would typically be displayed on a TradingView page.
